Fundraising Fox
Hilltop Bio
Norwood, US · Founded 2018 · 21 employees on LinkedIn · 6 known investors
Find your way into Hilltop Bio
Sign up to see every warm intro you have to Hilltop Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Hilltop Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Hilltop Bio develops bioscaffold and therapeutic products for veterinary use, including wound care, joint health, soft tissue repair, and ophthalmic solutions for equine and small animal patients.
Founders & leadership
MW
Mark WilliamsVice President Of Business Development2018–2025Mark Williams is an executive officer and director at Hilltop Bio, a developer of bioscaffold and therapeutic products for veterinary use. He brings experience in sales, marketing, and reimbursement operations, including speaker program development and relationships with healthcare institutions.
AD
Amanda DrobnisCEO/Co-FounderAmanda Drobnis is co-founder and CEO of Hilltop Bio, which develops bioscaffold and therapeutic products for veterinary wound care, joint health, and tissue repair. She has prior experience in animal-focused marketing roles at PetSmart and PetSmart Charities, as well as medical device distribution, and holds a background in animal science.
Board
Investors · 6
Launchpad Venture Grouplisted by Launchpad Venture GroupBoston · $8M – $10M
How we know: the VCSheet dataset · Not right? Tell us
RevUp Capitallisted by RevUp CapitalBoston
How we know: RevUp Capital's portfolio page · Not right? Tell us
Walnut Venture Associateslisted by Walnut Venture AssociatesWellesley
How we know: the VCSheet dataset · Not right? Tell us
Golden SeedsreportedFlushing · $250K – $2M
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$7.8M disclosed across 5 rounds · 2019–2024
▶$5.3MraisedMar 2025 · 73 investors · BiotechnologyRule 506(b)
▶$5.3MraisedMar 2025 · 73 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark WilliamsExecutive Officer, Director
- Jessica McLearDirector
- Alan WatsonDirector
- Denise BeversDirector
- Amanda DrobnisExecutive Officer, Director
- Offering amount
- $5.5M
- Amount sold
- $5.3M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$723.5KraisedApr 2023 · 42 investors · BiotechnologyRule 506(b)
▶$723.5KraisedApr 2023 · 42 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Amanda DrobnisExecutive Officer, Director
- Alan WatsonDirector
- Denise BeaversDirector
- Mark WilliamsDirector
- Jessica McLearDirector
- Offering amount
- $1M
- Amount sold
- $723.5K
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$866.3KraisedOct 2021 · 67 investors · BiotechnologyRule 506(b)
▶$866.3KraisedOct 2021 · 67 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark WilliamsExecutive Officer, Director
- Jessica McLearDirector
- Denise BeversDirector
- Alan WatsonDirector
- Amanda DrobnisExecutive Officer, Director
- Offering amount
- $1.4M
- Amount sold
- $866.3K
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$149.7KraisedMay 2020 · 21 investors · BiotechnologyRule 506(b)
▶$149.7KraisedMay 2020 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Denise BeversDirector
- Jill WittelsDirector
- Amanda DrobnisExecutive Officer, Director
- Jessica McLearDirector
- Mark WilliamsExecutive Officer, Director
- Offering amount
- $450K
- Amount sold
- $149.7K
- First sale
- May 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$750.9KraisedJul 2019 · 48 investors · BiotechnologyRule 506(b)
▶$750.9KraisedJul 2019 · 48 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark WilliamsExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $750.9K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Hilltop Bio do?
- Hilltop Bio develops bioscaffold and therapeutic products for veterinary use, including wound care, joint health, soft tissue repair, and ophthalmic solutions for equine and small animal patients.
- Who are Hilltop Bio's investors?
- Hilltop Bio's investors include Band of Angels, Beacon Angels, Launchpad Venture Group, RevUp Capital, Walnut Venture Associates, Golden Seeds.
- How much funding has Hilltop Bio raised?
- Hilltop Bio has disclosed $7.8M raised across 5 rounds.
- Where is Hilltop Bio headquartered?
- Hilltop Bio is headquartered in Norwood, US.